CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 100 target
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02644369
NCT02644369Phase 2ActiveOn Track
CompareCT.gov

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

University Health Network, Toronto·interventional·Posted Dec 31, 2015·Updated Jun 8, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for Squamous Cell Cancer of Head and Neck and 4 related conditions. Active but no longer recruiting, targeting 100 participants across 1 site.

Detailed Summary

This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment. Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma, Advanced Solid Tumors
CountriesCanada
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
201620172018201920202021202220232024202520262027
First PostedDec 31, 2015
Enrollment StartMar 21, 2016
Primary CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 10.7 yearsPosted 10.5 years agoPrimary completion in 5 months

Interventions

Pembrolizumabbiological

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.